Aptamer Group (LSE:APTA) shares advanced last week after its directors voluntarily agreed not to exercise low-priced board Options until the share price holds above 0.6p, a move followed days later by board and Leadership changes.

What's happening

Aptamer Group plc, the AIM-quoted developer of Optimer binders, was among the notable small-cap movers of the past week. The shares advanced 28% in the week to 13 November 2026 after the company's directors agreed to restrict the exercise of share options previously awarded to the board. Those options cover 193.5 million shares at an exercise price of 0.1p, and the directors committed not to exercise them until the share price remains above 0.6p for 30 consecutive trading days.

The reason is straightforward. Options priced far below the market can create selling pressure if exercised and sold. By tying exercise to a sustained share price six times the option price, the board has linked any exercise to a materially higher valuation. The change was set out in an announcement titled "Voluntary Price Condition on Directors' Options", dated 12 November 2026.

The latest announcements

In its 12 November 2026 announcement, the company imposed a voluntary three-year share price condition on 193,508,199 director options, described as "Award 1", carrying an exercise price of 0.10p. These options cannot be exercised until the closing mid-market price exceeds 0.6p for 30 consecutive dealing days. None of the options has yet been exercised, and any disposals after exercise will be subject to 12-month orderly market arrangements. The announcement did not name the individual directors involved.

The same announcement set the move in the context of the wider incentive structure. Awards made in August 2026 totalled 863,785,988 options, including:

  • 227,182,788 "Award 2" options at 0.60p, which vest after a 0.65p hurdle measured over 30 days;
  • 443,095,001 "Award 3" options at 0.69p, with price hurdles ranging from 1.5x–3.25x;
  • The surrender of 444,758,842 options that had been granted in 2024.

Those awards followed a £4.55m fundraise at 0.6p. The 0.6p hurdle on the older, low-priced options therefore matches the price at which new investors recently subscribed.

A second announcement followed on 16 November 2026, titled "Board and Senior Leadership Changes". Dr Paloma Giangrande has been appointed as a Non-Executive Director. Her prior programmes were acquired by Bristol Myers Squibb for US$1.5 billion, and she holds no ordinary shares in the company. Dr James McNamara becomes Head of Oligonucleotide Therapeutic Development, while Dr David Bunka steps down from the Board to focus on R&D.

The same update included operational progress points. Management said its AI/ML build had been completed six months early, automation had been integrated and lead candidate generation had started. The first in vivo Optimer-targeted radiotherapy study is under way, with in vivo studies having been funded in March 2026.

The Business at a glance

Aptamer Group's recent news flow points to a growing emphasis on Optimer-based therapeutic delivery alongside its work with pharmaceutical partners and its licensing activity.

On 26 October 2026 the company announced a collaboration with Pharmahungary Group, a biotechnology company focused on microRNA (miRNA) therapeutics. The partners aim to develop two Optimer delivery vehicles, one directed to heart muscle cells and one to skeletal muscle. The deal is structured on a cost-sharing basis: each party funds its own work and retains its own intellectual property. Aptamer funds the development and validation of the targeting system and manufactures Optimer-conjugates carrying Pharmahungary's miRNA, while Pharmahungary funds and runs the preclinical studies, both in vitro and in vivo.

Aptamer (LSE:APTA) retains full ownership of its delivery vehicles and associated intellectual property and owns 50% of the combined Optimer-miRNA therapeutic. If the work succeeds, the companies intend to pursue licensing jointly with pharmaceutical partners. The announcement noted that a comparable preclinical study package would typically cost £300,000 to £500,000, and that the deal requires no unbudgeted expenditure and does not alter the company's cash runway projections. It also cited a forecast that the oligonucleotide therapeutics market could reach US$17.7 billion by 2030. Pharmahungary brings over 25 years of cardiovascular development work experience and has completed more than 350 preclinical projects.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said: "Pharmahungary Group is a leading authority in cardiac miRNA, and we are delighted that it has chosen Optimer® technology". Professor Péter Ferdinandy, Founder and Chief Executive Officer of Pharmahungary Group, said: "Our goal is to generate the in vivo evidence needed to take this combined approach to pharmaceutical partners."

Financial position

Aptamer published full-year results for the 12 months to 30 June 2026 on 13 October 2026. Revenue rose 28% to £1.5 million, while the adjusted EBITDA loss was £2.3 million and administration expenses were £3.2 million. The company held cash of £4.4 million at the year end, following a £4.1 million share issue, and the company described the cash runway as extending "into calendar 2028".

The sales pipeline had risen to £7.0 million by September 2026, and the company said it is moving key pharmaceutical relationships to multi-year master service agreements. It also signed new licensing agreements for enzyme-modulating Optimers during the period.

Factors to watch

The rally reflects improved sentiment around governance, but several risks remain relevant for anyone following the company:

  • Dilution: the options in issue are large relative to a small-cap share base. Even with the new price conditions, exercise of the various awards would add new shares over time, and the business has relied on Share Capital raises such as the £4.55m fundraise.
  • Losses and funding: the company remains loss-making at the adjusted EBITDA level. Its runway guidance depends on delivering pipeline conversion and controlling costs; any shortfall could lead to further fundraising.
  • Scale of revenue: revenue of £1.5 million is modest compared with the £7.0 million pipeline, and pipeline figures are not the same as contracted income.
  • Development risk: therapeutic delivery programmes, including the Pharmahungary collaboration and the radiotherapy study, are at preclinical stages, and success is not assured.

The bottom line

Aptamer Group (LSE:APTA)'s share price rise last week followed a governance move rather than a trading update: directors agreed not to exercise 193,508,199 options at 0.10p until the shares stay above 0.6p for 30 consecutive dealing days. The appointment of Dr Paloma Giangrande and the operational update add to the news flow. Points to watch include conversion of the £7.0 million pipeline, progress with Pharmahungary, and whether the shares can hold around the 0.6p reference point.